Bharat Biotech completes clinical trial for nasal Covid-19 vaccine

Chairman and MD of Bharat Biotech Dr Krishna Ella said that the data analysis is going on for the world’s first nasal Covid vaccine.

Bharat Biotech completes clinical trial for the world’s first nasal Covid vaccine. (Image for representation: AFP)

The Chairman and MD of Bharat Biotech, Dr Krishna Ella, said that they have completed a clinical trial for the world’s first clinically proven nasal Covid-19 vaccine. “Data analysis is going on. We’ll submit the data to regulatory agency. If everything is okay, we’ll get permission to launch & it will be world’s 1st clinically proven nasal Covid-19 vaccine,” Dr Krishna Ella was quoted as saying by ANI.

The Drugs Controller General of India’s (DCGI) Subject Expert Committee (SEC) gave an ‘in-principle’ approval to Bharat Biotech for the ‘phase-III booster dose study’ for its intranasal Covid vaccine, a first of its kind in India, and asked it to submit protocols for approval a few weeks ago.

WATCH | Bharat Biotech seeks nod for intranasal Covid-19 vaccine as booster Dose

As per Bharat Biotech’s website, “An intranasal vaccine stimulates a broad immune response neutralising IgG, mucosal IgA, and T cell responses and creates an immune response at the site of infection (in the nasal mucosa) essential for blocking both infection and transmission of Covid-19.”

Bharat Biotech is the second company to submit an application for the phase-III trial of the third dose in India. The intranasal vaccines reportedly have the potential to prevent transmission for new Covid-19 variants such as Omicron.

India has approved Covidshield, Covaxin and Sputnik V for vaccination in the country. Covaxin is approved for use under the 28-day Multi-Dose Vial Policy (MDVP) from DCGI and the WHO Emergency Use Listing (WHO EUL).

Read More